Author: Rebecca Shover

This year’s ASH was exceptionally busy, with overlapping sessions, including three back-to-back myeloma talks. Key studies showcased practice-changing findings.

A review of treatments for TP53m MCL found high response rates with targeted and CAR-T therapies but highlighted poor survival, urging innovative strategies.

First-line, fixed-duration ibrutinib plus venetoclax provides durable progression-free survival and overall survival for patients with CLL or SLL.

An online mindfulness-based stress reduction program reduced the symptomatic burden for patients with breast cancer, according to research from SABCS.

Using AI and remote patient monitoring technology in pain management enables ongoing real-time monitoring, facilitating personalized adjustments to therapy.

A new patient registry aims to integrate clinical and patient-reported data to improve care and guide personalized treatment in early breast cancer.

Luis Sumoza, MD, highlights the need to explain the disease, its consequences, and treatment side effects to patients, highlighting effective communication with primary care providers is crucial to ensure coordinated care.

Physician’s Weekly spoke with Richard Newcomb, MD, on the role of nurses and APs in enhancing palliative care.

Early palliative care improves transplant patients’ quality of life, especially for minoritized groups or those with high distress, suggesting targeted or clinician-led care.

iMMagine-1 phase 2 trial shows 97% response, 62% complete response in relapsed/refractory myeloma, with strong safety and promising 2026 launch.